- Home
- BCYC
as 01-17-2025 4:00pm EST
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
| Founded: | 2009 | Country: | United Kingdom |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.7B | IPO Year: | 2019 |
| Target Price: | $34.50 | AVG Volume (30 days): | 412.4K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.17 - $28.67 | Next Earning Date: | 02-18-2025 |
| Revenue: | $36,898,000 | Revenue Growth: | 48.60% |
| Revenue Growth (this year): | 40.69% | Revenue Growth (next year): | -18.88% |
Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Jan 2 '25 | Sell | $14.42 | 4,223 | $60,119.83 | 123,722 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Jan 2 '25 | Sell | $14.42 | 2,118 | $30,000.36 | 55,280 | |
| Crockett Nigel | BCYC | CHIEF BUSINESS OFFICER | Jan 2 '25 | Sell | $14.42 | 3,519 | $50,200.47 | 51,989 | |
| Young Alethia | BCYC | Chief Financial Officer | Jan 2 '25 | Sell | $14.09 | 1,395 | $19,655.55 | 45,605 | |
| Milnes Alistair | BCYC | CHIEF OPERATING OFFICER | Jan 2 '25 | Sell | $14.42 | 5,514 | $78,310.02 | 99,788 | |
| Lee Kevin | BCYC | CHIEF EXECUTIVE OFFICER | Jan 2 '25 | Sell | $14.42 | 12,130 | $172,952.42 | 491,934 | |
| BAKER BROS. ADVISORS LP | BCYC | Director10% Owner | Dec 13 '24 | Buy | $14.00 | 1,485,397 | $21,230,384.81 | 9,537,643 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Nov 11 '24 | Sell | $24.99 | 6,256 | $157,113.55 | 22,922 |
Latest Bicycle Therapeutics plc News
BCYC Breaking Stock News: Dive into BCYC Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
Business Wire
9 days ago
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Business Wire
15 days ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barrons.com
a month ago
First Solar, Frontier Communications, and More Stocks See Action From Activist Investors
MT Newswires
a month ago
B. Riley Adjusts Price Target on Bicycle Therapeutics to $17 From $28, Keeps Neutral Rating
MT Newswires
a month ago
Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump
Benzinga
a month ago
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Simply Wall St.
a month ago
We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely
Compare BCYC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCYC Bicycle Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.